Advertisement

Advertisement

CLNN Stock Latest News

Clene Extends Note Maturities and Expands Equity Plan

Company AnnouncementsClene Extends Note Maturities and Expands Equity Plan

Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’

PremiumThe Fly

Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’

9d ago

Analyst Reiterates Buy on Advancing CNM-Au8 ALS Pathway and Funding Visibility; $31 Price Target Maintained

PremiumRatings

Analyst Reiterates Buy on Advancing CNM-Au8 ALS Pathway and Funding Visibility; $31 Price Target Maintained

9d ago

Clene reports Q1 EPS (69c), consensus (70c)

PremiumThe Fly

Clene reports Q1 EPS (69c), consensus (70c)

9d ago

Clene Extends Debt Maturities and Strengthens Cash Runway

PremiumCompany Announcements

Clene Extends Debt Maturities and Strengthens Cash Runway

9d ago

CLNN Earnings this Week: How Will it Perform?

PremiumPre-EarningsCLNN Earnings this Week: How Will it Perform?

12d ago

Clene price target raised to $50 from $48 at Canaccord

The Fly

Clene price target raised to $50 from $48 at Canaccord

15d ago

Clene Announces $7 Million Registered Direct Equity Offering

Company Announcements

Clene Announces $7 Million Registered Direct Equity Offering

18d ago

Clene provides update on NDA for ALS following Type C meeting with FDA

PremiumThe Fly

Clene provides update on NDA for ALS following Type C meeting with FDA

19d ago

Clene Advances CNM-Au8 Toward Accelerated ALS Approval

PremiumCompany Announcements

Clene Advances CNM-Au8 Toward Accelerated ALS Approval

19d ago

Clene, Lovesac, HDFC Bank, State Street, Vor Shock

PremiumWeekend Updates

Clene, Lovesac, HDFC Bank, State Street, Vor Shock

28d ago

Surf Air, Cytokinetics, ASE, Itau, Clene Insider Shake-Up

PremiumWeekend Updates

Surf Air, Cytokinetics, ASE, Itau, Clene Insider Shake-Up

1M ago

Insiders Cash Out: Cytokinetics, Itau, ASE, Clene, Black Stone

PremiumWeekend UpdatesInsiders Cash Out: Cytokinetics, Itau, ASE, Clene, Black Stone

1M ago

Clene Secures Third-Year NIH Subaward for ALS Program

Company Announcements

Clene Secures Third-Year NIH Subaward for ALS Program

2M ago

Clene reports FY25 EPS ($2.65), consensus ($2.35)

The Fly

Clene reports FY25 EPS ($2.65), consensus ($2.35)

2M ago

Clene outlines 2026 regulatory milestones and ALS strategy

PremiumCompany Announcements

Clene outlines 2026 regulatory milestones and ALS strategy

3M ago

Clene issues letter to shareholders on CNM-Au8 2026 catalysts

PremiumThe Fly

Clene issues letter to shareholders on CNM-Au8 2026 catalysts

3M ago

Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed

PremiumWeekend Updates

Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed

4M ago

Clene Announces Multi-Tranche Financing to Extend Cash Runway

PremiumCompany Announcements

Clene Announces Multi-Tranche Financing to Extend Cash Runway

4M ago

Clene Advances CNM-Au8 ALS Program with FDA Meeting

PremiumCompany AnnouncementsClene Advances CNM-Au8 ALS Program with FDA Meeting

4M ago

Clene announces additional CNM-Au8 biomarker data for potential NDA filing

The Fly

Clene announces additional CNM-Au8 biomarker data for potential NDA filing

4M ago

Clene announces over $28M registered direct offering

The Fly

Clene announces over $28M registered direct offering

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >